Literature DB >> 23892676

[Trends of use of anxiolytics and hypnotics in Spain from 2000 to 2011].

María Pilar Vicente Sánchez1, Diego Macías Saint-Gerons, César de la Fuente Honrubia, Diana González Bermejo, Dolores Montero Corominas, Ferrán Catalá-López.   

Abstract

BACKGROUND: For years, anxiolytics and hypnotics have been one of the most prescribed drug classes in most developed countries. The main aim of this study is to explore the pattern of use of anxiolytic and hypnotic drugs during the period 2000-2011, comparing their growth with that of five european countries.
METHOD: We performed an ecological and descriptive study of anxiolytics and hypnotics consumption in Spain. Consumption data were obtained from the databases of medications dispensed in community pharmacies and charged through official prescriptions to the totality of the Spanish National Health System. Annual and total-period consumptions were expressed in defined daily doses (DDD) per 1000 inhabitants per day (DDD/1000 person/day) by each treatment subgroup, active substance and attending the plasma half-life of the medication. Approximate comparisons were also made with some European countries.
RESULTS: The use of anxiolytics and hypnotics drugs was 56.7 DDD/1000 person/day in 2000 and 82.9 DDD/1000 person/day in 2011 (a +46.1% increase across the period). Lorazepam and alprazolam were the most used anxiolytics (20.5 and 15.6 DDD/1000 person/day in 2011, respectively), whereas lormetazepam was among the hypnotics (18.3 DDD/1000 person/day in 2011). In relative terms, hypnotics´ lormetazepam and zolpidem increased their use by 103.3% and 85.1%, respectively; while anxiolytics´ lorazepam and hydroxyzine increased 75.1% and 72.8%, respectively. In Spain (period 2003-2010), the total increase in the consumption of anxiolytics and hypnotics was +34.3%, with 24.0% for Portugal, 4.0% for Italy, but a reduction of -6.1% for France.
CONCLUSIONS: A considerable increase in anxiolytics and hypnotics´ consumption has occurred in Spain during the last decade, being the growth higher than that reported in other European countries.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23892676     DOI: 10.4321/S1135-57272013000300004

Source DB:  PubMed          Journal:  Rev Esp Salud Publica        ISSN: 1135-5727


  11 in total

1.  Effects of a primary care intervention to improve the quality of zolpidem prescriptions in elderly patients.

Authors:  Rocío López-Sepúlveda; María Ángeles García Lirola; Esther Espínola García; Salvadora Martín Sances; Sonia Anaya Ordóñez; José María Jurado Martínez; José Cabeza Barrera
Journal:  Eur J Clin Pharmacol       Date:  2016-12-27       Impact factor: 2.953

2.  Evaluation of Risk Factors Associated to Prescription of Benzodiazepines and its Patterns in a Cohort of Patients from Mental Health: A Real World Study in Spain.

Authors:  Jorge Simal-Aguado; María-Pilar Campos-Navarro; Francisco Valdivia-Muñoz; Alejandro Galindo-Tovar; Juan Antonio García-Carmona
Journal:  Psychopharmacol Bull       Date:  2021-01-12

3.  Effects of the Financial Crisis on Psychotropic Drug Consumption in a Cohort from a Semi-Urban Region in Catalonia, Spain.

Authors:  Maria A Barceló; Montserrat Coll-Negre; Gabriel Coll-de-Tuero; Marc Saez
Journal:  PLoS One       Date:  2016-02-12       Impact factor: 3.240

4.  Time Trend in Psychotropic Medication Use in Spain: A Nationwide Population-Based Study.

Authors:  Pilar Carrasco-Garrido; Valentín Hernández-Barrera; Isabel Jiménez-Trujillo; Jesús Esteban-Hernández; Alejandro Álvaro-Meca; Ana López-de Andrés; José Luis DelBarrio-Fernández; Rodrigo Jiménez-García
Journal:  Int J Environ Res Public Health       Date:  2016-11-24       Impact factor: 3.390

5.  [An integral approach to insomnia in primary care: Non-pharmacological and phytotherapy measures compared to standard treatment].

Authors:  M Adela Viniegra Domínguez; Neus Parellada Esquius; Rafaela Miranda de Moraes Ribeiro; Laura Mar Parellada Pérez; Carme Planas Olives; Cristina Momblan Trejo
Journal:  Aten Primaria       Date:  2014-10-28       Impact factor: 1.137

6.  [Prevalence of insomnia and characteristic of patients with insomnia in a health area of Majorca (Spain)].

Authors:  Isabel Torrens; Rosmary Argüelles-Vázquez; Patricia Lorente-Montalvo; Carlos Molero-Alfonso; Magdalena Esteva
Journal:  Aten Primaria       Date:  2019-03-08       Impact factor: 1.137

7.  Gender Differences in the Prevalence of Mental Health, Psychological Distress and Psychotropic Medication Consumption in Spain: A Nationwide Population-Based Study.

Authors:  Clara Maestre-Miquel; Ana López-de-Andrés; Zichen Ji; Javier de Miguel-Diez; Arturo Brocate; Sara Sanz-Rojo; Antonio López-Farre; David Carabantes-Alarcon; Rodrigo Jiménez-García; José J Zamorano-León
Journal:  Int J Environ Res Public Health       Date:  2021-06-11       Impact factor: 3.390

8.  Analysis of changes in trends in the consumption rates of benzodiazepines and benzodiazepine-related drugs.

Authors:  Miguel Angel Fernández García; Antonio Olry de Labry Lima; Ingrid Ferrer Lopez; Clara Bermúdez-Tamayo
Journal:  J Pharm Policy Pract       Date:  2018-01-16

9.  Intervention to reduce benzodiazepine prescriptions in primary care, study protocol of a hybrid type 1 cluster randomised controlled trial: the BENZORED study.

Authors:  Caterina Vicens; Alfonso Leiva; Ferran Bejarano; Ermengol Sempere; Raquel María Rodríguez-Rincón; Francisca Fiol; Marta Mengual; Asunción Ajenjo; Fernando Do Pazo; Catalina Mateu; Silvia Folch; Santiago Alegret; Jose Maria Coll; María Martín-Rabadán; Isabel Socias
Journal:  BMJ Open       Date:  2019-01-30       Impact factor: 2.692

10.  [Attitudes to insomnia by Primary Care physicians of Majorca (Spain)].

Authors:  Isabel Torrens; Marina Ortuño; Juan Ignacio Guerra; Magdalena Esteva; Patricia Lorente
Journal:  Aten Primaria       Date:  2015-11-02       Impact factor: 1.137

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.